Patient Support

Direct-to-consumer and direct-to-patient models are major contributors.

The rebrand creates a platform that is expected enhance the way life sciences companies bring their therapies to market.

The telehealth site will welcome its own small-dose, compounded version of semaglutide, which mimics the function of a GLP-1.

An NEJM study explores how this loss—following Medicaid disenrollment—affects beneficiaries.

A qualitative study aimed to strengthen systematic repurposing efforts within rare disease nonprofit organizations, while also providing a framework for data-driven drug repurposing.

Ways to reimagine pharma’s operating model and KPIs for commercial success in an AI-driven future.

The move bolsters the CDMO’s commitment to cell and gene therapy by incorporating advanced manufacturing and fill-finish capabilities.

As the adoption of biologics rises, demand for home healthcare grows, and conditions like diabetes and autoimmune disorders become more prevalent, self-injectables are here to stay.

A multi-national study reveals over half of older adults in several European countries are prescribed five or more medications—spotlighting the urgent need for better data-driven prescribing strategies.

Subject matter experts share the challenges that patients face in terms of medication affordability, along with the role that specialty pharmacies can play in helping to tackle these issues.

Will Pih, co-founder, Two Labs, explains how specialty pharmacies and manufacturers are adapting to financial pressures in rare disease care through patient-centric services, hub innovation, and hybrid technology models.

A panel of experts examines how stakeholders can support strategies that improve patient outcomes, while also navigating various distribution models.

Chip Parkinson, CEO, GiftHealth, explains how AI, real-time data, and closer payer collaboration are driving the next phase of growth and efficiency in specialty pharmacy.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Paul Levesque, CEO of Theratechnologies, describes the uneasiness behind regulatory complications.

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Paul Levesque, CEO of Theratechnologies, explains what the mindset be for companies who are just starting the reshoring process.

A survey study takes a closer look into which medications patients would like to have deprescribed, along with the reasons and factors influencing that decision.

The Carlsbad plant is expected to accelerate both the development and commercialization of cell therapies.

In the final part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Rachel Thorpe, executive director at the Otsuka Patient Assistance Foundation, emphasizes the importance of the separation of core business and foundation, the value of patient empowerment, and the impact of digital innovation.

Access USA converges in Philadelphia to explore new—and needed—solutions to boost patient outcomes.

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Chris O’Dell, provides an update on where the healthcare industry currently stands in terms of compliance with price transparency regulations, and what steps need to be taken to achieve full compliance.

A panel discussion uncovers ways to deliver personalized therapy ops in a timely fashion.

The key strategies for reducing or eliminating post-prescription abandonment.

In the final part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Kimberly Westrich, chief strategy officer at the National Pharmaceutical Council, comments on another presentation that has caught her eye at the conference.

A look at the prevailing factors impacting treatment access in 2025.

How pharma manufacturers can steadily navigate GTN components and complexities when planning pharmacy benefit reimbursement.